Trial Profile
Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms XelOx-P07
- 08 Dec 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 25 Jul 2011 New trial record